Isomorphic Labs, the AI drug-discovery company founded by Demis Hassabis, has raised $5 billion in a Series C round to advance its efforts to design medicines with artificial intelligence. The financing was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz and Alphabet also participating. Hassabis, who remains Isomorphic’s CEO, stepped back from leading Google DeepMind three and a half months before the fundraising announcement. Isomorphic spun out of DeepMind in 2021, and its latest round follows a $2.1 billion Series B in May.
The company is developing a proprietary AI drug-design engine, foundational models of biology, and a pipeline of potential therapies. Hassabis says the funding will support deeper understanding of disease and move the company’s first treatment programs toward clinical trials, with the aim of producing medicines that benefit patients. The raise reflects a broader surge of investment in AI-enabled drug development: startups in the field attracted a record $23.2 billion in 2026, according to Dealroom. Major AI companies are also entering the area: Anthropic launched a drug-discovery program in June, while OpenAI partnered with Novo Nordisk in April.
Summary generated by AI from the linked article. hn.today is not affiliated with Hacker News or Y Combinator.